Xgene’s non-opioid analgesic reduces pain in Phase IIb trial
Taiwanese pharmaceutical company Xgene Pharmaceutical announced that its non-opioid analgesic drug XG005 has reduced acute pain in patients after surgery …
Post
-
-
Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst
Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity …
-
University of Birmingham launches trial for paediatric B-NHL treatment in UK
The University of Birmingham has launched the global ‘Glo-BNHL’ clinical trial assessing new therapies to treat paediatric patients with B-cell …
-
China leads rare disease trials from 2020
According to GlobalData’s Clinical Trials Database, non-industry sponsored trials lead rare disease indications, accounting for 55.6% of all trials since …
-
Cocrystal to extend enrolment in Phase IIa influenza inhibitor trial
Cocrystal Pharma has announced its intent to extend enrolment for its Phase IIa human challenge trial of the oral influenza …
-
IMCA renews SciSparc’s autism spectrum disorder therapy trial approval
Israeli Medical Cannabis Agency (IMCA) at the Ministry of Health has renewed SciSparc’s clinical trial of SCI-210 aimed at treating …
-
Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint
Novartis has reported positive topline outcomes from the Phase III STEER trial of an investigational gene therapy, intrathecal onasemnogene abeparvovec …
-
Sensorion completes first cohort enrolment in Phase I/II gene therapy trial
Sensorion has completed subject enrolment in the first cohort of Phase I/II Audiogene trial of gene therapy injection, SENS-501 for …
-
China’s CDE approves Alphamab’s IND to begin Phase I/II trial of JSKN033
China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has approved Alphamab Oncology’s investigational new drug application (IND) …
-
Ractigen doses first subject in Phase I ALS treatment trial
Ractigen Therapeutics has dosed the first subject in the randomised Phase I clinical trial of its small interfering RNA (siRNA) …
-
XBiotech halts all rheumatology research after missing Phase II endpoints
XBiotech’s stock price has taken a hit after it announced a complete halt to its clinical program in rheumatological diseases …
-
Arrowhead doses first patient in Phase I/IIa RNA obesity therapy trial
California company Arrowhead Pharmaceuticals has announced that it has dosed the first patient as part of its new Phase I/IIa …
-
One-third of psoriatic arthritis cases undiagnosed in key pharma markets
Psoriatic arthritis (PsA) is a chronic inflammatory disease that causes joint pain, stiffness and swelling. Symptoms can vary widely, making …
-
Sodium intake linked to atopic dermatitis and disease severity
Atopic dermatitis (AD) is the most common type of eczema. It is a chronic skin condition that causes inflammation, skin …
-
Striking increase in syphilis detected by new screening approach
Syphilis is a common sexually transmitted infection (STI) that is curable if detected and treated early. However, if left untreated, …
